FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Track all the latest updates and news of Ajooni Biotech IPO.
March 14, 2024 2:30:00 PM
Biotechnology IPOs tend to do well over the long term just as financing markets begin to thaw, an analysis shows.
Published by : Wall Street Journal on MSNMarch 15, 2024 9:26:28 AM
The biotech industry is currently experiencing a period of cautious optimism, presenting potential opportunities ...
Published by : The UBJ on MSNMarch 24, 2023 2:07:00 PM
Ajooni Biotech Ltd share price was down by -2.91% ... spat Setback for finfluencers as Sebi asks audiovisual details of IPO disclosures Big jolt to Congress: Himachal chief Pratibha Singh says ...
Published by : Business TodayMay 5, 2017 3:30:00 AM
The biotech IPO market seems to be heating up after three stock market launches in quick succession, including the largest launch seen in the sector this year. After a boom in 2014 and 2015 ...
Published by : pharmaphorumMarch 6, 2024 7:50:00 PM
Just when it seemed like the biotech IPOs were being lulled back to sleep, Boundless Bio says it plans to hit Wall Street. The Arch-, Bayer- and RA-backed company filed an S-1 Wednesday afternoon ...
Published by : FierceBiotechMay 19, 2020 3:30:00 AM
Legend Biotech is spinning out from parent firm GenScript Biotech to pursue treatments in CAR T cell therapies for multiple myeloma. Legend Biotech is spinning out from parent firm GenScript ...
Published by : TheStreet.comOctober 12, 2023 9:50:00 PM
After a decade of significant challenges, biotech's long-term sustainability depends on making fundamental changes to its traditional business model. A commonly held perception in the biotech ...
Published by : NatureMarch 5, 2024 2:30:00 AM
Those IPOs, combined with the recovery of biotech�s two flagship stock funds and a dealmaking surge, have given industry watchers reasons to be optimistic. �Some of the trends that are going ...
Published by : Yahoo FinanceMarch 15, 2024 6:19:00 AM
Biotechnology IPOs tend to do well over the long term just as financing markets begin to thaw, an analysis shows. The best time to make money in biotech is usually during periods of cautious optimism.
Published by : MintMarch 14, 2024 3:30:00 PM
The best time to make money in biotech is usually during periods of cautious optimism. There are strong signs that right now might be one of those moments. The always-volatile industry has just ...
Published by : Wall Street JournalThe issue of Ajooni Biotech Limited opens on Dec 20, 2017 and closes for subscription on Dec 22, 2017. The equity shares of the company to be list at NSE SME. The price band for the issue has been fixed at Rs 30.
Ajooni Biotech Limited is entering in the capital market with an IPO of 21,96,000 Equity Shares of Rs 10 aggregating up to Rs. 6.59 Crore. The price band for the issue has been fixed at Rs 30 Per Equity Share.
Incorporated in 2010, Ajooni Biotech Limited is Mohali, Punjab based company engaged in manufacturing, producing, processing and supplying of Cattle feed, Nutrients related to cattle feed and manufacturing & production of Animal health care supplements.
The issue opens on Dec 20, 2017 and closes for subscription on Dec 22, 2017. The equity shares of the company to be list at NSE SME platform.
The Ajooni Biotech IPO is proposed to open on December 20, 2017. The IPO application ends on December 22, 2017.
Retail investors can apply in the retail or non-institutional investor category from December 20, 2017 to December 22, 2017. The Ajooni Biotech IPO can be applied online through Net Bank (ASBA method) or the stock broker (UPI method).
The Ajooni Biotech IPO will open for subscription on December 20, 2017. The public issue will close on December 22, 2017.
Useful Articles
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|